髄芽腫治療薬の世界市場レポート 2025年

髄芽腫治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6％で42億5,000万米ドルに成長します。今後、予測期間の成長は、髄芽腫を対象とした臨床試験の拡大、精密医療と個別化治療の選択肢の進歩、がん領域における併用療法の需要増、希少疾患・希少疾病の治療薬開発への重点化、新薬承認に向けた良好な規制環境などが牽引するとみられます。予測期間の主な動向としては、併用療法の開発、創薬における人工知能の統合、脳腫瘍検出のためのリキッドバイオプシー技術の進歩、標的腫瘍治療のための遺伝子治療におけるブレークスルー、製薬企業と研究機関の連携などが挙げられます。

脳腫瘍の発生件数の増加が、今後数年間の髄芽腫治療薬市場の成長を牽引すると予想されます。脳腫瘍は脳や脊柱管に発生する異常な細胞増殖であり、良性または悪性の可能性があり、脳機能を損なう可能性があります。脳腫瘍患者の増加は、検出方法の改善、高齢化、環境要因、意識の高まり、遺伝的要因に起因します。髄芽腫の治療には、化学療法、放射線療法、標的療法などがあり、腫瘍を縮小させ、がん細胞を死滅させ、転移を防ぐことを目的としています。例えば、2022年10月、米国国立衛生研究所は、米国では原発性脳腫瘍の新規症例が2022年の93,470例から2023年には94,390例に増加したと報告しました。その結果、脳腫瘍の増加が髄芽腫治療薬の市場拡大に寄与しています。

また、ヘルスケア支出の拡大も髄芽腫治療薬市場の成長を加速させると予想されます。ヘルスケア支出には、医療サービス、医薬品、予防医療、インフラストラクチャー、政府および民間部門による管理費などの総支出が含まれます。この支出は、高齢化、医療の進歩、慢性疾患率の上昇、管理コストの上昇などの要因により増加しています。ヘルスケア支出の増加は、研究、臨床試験、革新的治療に資金を提供することで髄芽腫治療薬の開発を支援し、医療技術の進歩や希少疾患の専門的治療を促進します。例えば、2024年12月、メディケア＆メディケイドサービスセンターは、2023年の病院支出は10.4％増の1兆5,197億米ドルに達し、2022年の3.2％増を上回ったと報告しました。同様に、2023年の処方薬支出は11.4％増の4,497億米ドルで、2022年の7.8％増を上回りました。したがって、ヘルスケア支出の増加が髄芽腫治療薬市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界髄芽腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の髄芽腫治療薬市場：成長率分析
• 世界の髄芽腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の髄芽腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界髄芽腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の髄芽腫治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジアンヒドロガラクチトール
• 治験薬5471
• イピリムマブ
• インドキシモド
• その他のタイプ
• 世界の髄芽腫治療薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法薬
• 標的治療薬
• 放射線治療薬
• 世界の髄芽腫治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• オーラル
• 脊髄内
• 世界の髄芽腫治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の髄芽腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の髄芽腫治療薬市場、ジアンヒドロガラクチトールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジアンヒドロガラクチトール経口製剤
• ジアンヒドロガラクチトール静脈内製剤
• 世界の髄芽腫治療薬市場、治験薬5471のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口治験薬5471
• 静脈内治験薬5471
• 世界の髄芽腫治療薬市場イピリムマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イピリムマブ単剤療法
• イピリムマブ併用療法
• 世界の髄芽腫治療薬市場インドキシモドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インドキシモド経口製剤
• インドキシモド併用療法
• 世界の髄芽腫治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テモゾロミド
• ロムスチン
• シクロホスファミド
• 標的治療薬

第7章 地域別・国別分析

• 世界の髄芽腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の髄芽腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 髄芽腫治療薬市場：競合情勢
• 髄芽腫治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Biocon Limited
• Teva Pharmaceutical Industries Ltd
• Eisai Co. Ltd.
• Ipsen S.A.
• Daiichi Sankyo Co. Ltd.
• Lumos Pharma Inc.
• Biodexa Pharmaceuticals plc
• Eagle Biosciences Inc.
• Cayman Chemical Company
• Biosynth Carbosynth AG
• Curtana Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 髄芽腫治療薬市場2029：新たな機会を提供する国
• 髄芽腫治療薬市場2029：新たな機会を提供するセグメント
• 髄芽腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Medulloblastoma drugs are medications used to treat medulloblastoma, a type of rapidly growing brain tumor that typically develops in the cerebellum or posterior fossa, mostly affecting children. The treatment approach usually combines surgery, radiation therapy, and chemotherapy. These drugs specifically target medulloblastoma, with most being chemotherapy agents.

Key types of medulloblastoma drugs include dianhydrogalactitol, investigational medicinal product 5471, ipilimumab, indoximod, among others. Dianhydrogalactitol is an alkylating agent used in cancer treatment, including for medulloblastoma. It works by interfering with the DNA of cancer cells, halting their ability to divide and grow. The drugs include chemotherapy agents, targeted therapy drugs, and radiation therapy drugs, which are administered via intravenous, oral, and intrathecal routes. These drugs are available through hospital pharmacies, online pharmacies, and retail pharmacies, serving a range of end users such as hospitals, home care settings, specialty centers, and others.

The medulloblastoma drug market research report is one of a series of new reports from The Business Research Company that provides medulloblastoma drug market statistics, including medulloblastoma drug industry global market size, regional shares, competitors with a medulloblastoma drug market share, detailed medulloblastoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the medulloblastoma drug industry. This medulloblastoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The medulloblastoma drug market size has grown strongly in recent years. It will grow from $2.80 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period can be attributed to several factors, including a rise in the incidence of pediatric brain tumors, increased investment in oncology-focused biotech companies, advancements in brain tumor diagnostic techniques, greater awareness of childhood cancer, and improved knowledge of tumor biology and genetics.

The medulloblastoma drug market size is expected to see strong growth in the next few years. It will grow to $4.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. Looking ahead, the growth in the forecast period is expected to be driven by an expansion of clinical trials targeting medulloblastoma, advancements in precision medicine and personalized treatment options, increased demand for combination therapies in oncology, a stronger emphasis on developing drugs for rare and orphan diseases, and a favorable regulatory environment for new drug approvals. Key trends for the forecast period include the development of combination therapies, the integration of artificial intelligence in drug discovery, progress in liquid biopsy techniques for brain tumor detection, breakthroughs in gene therapy for targeted tumor treatments, and collaboration between pharmaceutical companies and research institutions.

The increasing occurrence of brain tumors is expected to drive the growth of the medulloblastoma drug market in the coming years. A brain tumor is an abnormal cell growth in the brain or spinal canal, which can be either benign or malignant, potentially impairing brain function. The rise in brain tumor cases is attributed to improved detection methods, an aging population, environmental factors, heightened awareness, and genetic factors. Medulloblastoma treatments, such as chemotherapy, radiation, and targeted therapies, aim to shrink tumors, kill cancer cells, and prevent their spread. For example, in October 2022, the National Institutes of Health reported that in the US, new primary brain tumor cases increased from 93,470 in 2022 to 94,390 in 2023. As a result, the growing number of brain tumors is contributing to the market expansion for medulloblastoma drugs.

The growing healthcare expenditure is also expected to accelerate the growth of the medulloblastoma drug market. Healthcare expenditure encompasses the total spending on medical services, medications, preventive care, infrastructure, and administrative costs by both government and private sectors. This expenditure is increasing due to factors such as an aging population, medical advancements, rising chronic disease rates, and higher administrative costs. Increased healthcare spending supports the development of medulloblastoma drugs by financing research, clinical trials, and innovative treatments, thus driving progress in medical technology and specialized care for rare diseases. For instance, in December 2024, the Centers for Medicare & Medicaid Services reported that in 2023, hospital expenditures grew by 10.4% to $1,519.7 billion, surpassing the 3.2% increase in 2022. Similarly, prescription drug spending rose by 11.4% to $449.7 billion in 2023, exceeding the 7.8% growth observed in 2022. Hence, rising healthcare expenditures are fueling the growth of the medulloblastoma drug market.

Companies in the medulloblastoma drug market are focusing on advancements in drug development, such as chemotherapy treatments for brain tumors, to gain a competitive advantage. Temozolomide, a chemotherapy drug, is commonly used to treat certain brain tumors, including glioblastoma and, in some instances, medulloblastoma, by damaging cancer cell DNA to prevent their growth and division. For example, in August 2022, Accord Healthcare, Inc., a US-based generic pharmaceutical company, introduced a generic version of Carmustine, a chemotherapy drug important for treating medulloblastoma, a brain tumor often seen in children. The new formulation is available in two strengths, 50 mg and a larger 300 mg vial, streamlining treatment by reducing the need for multiple smaller vials. Carmustine, classified as an alkylating agent, works by disrupting cancer cell growth and is FDA-approved for use alone or in combination with other therapies for various cancers, including medulloblastoma, glioblastoma, and certain blood cancers.

Major players in the medulloblastoma drug market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Biocon Limited, Teva Pharmaceutical Industries Ltd, Eisai Co. Ltd., Ipsen S.A., Daiichi Sankyo Co. Ltd., Lumos Pharma Inc., Biodexa Pharmaceuticals plc, Eagle Biosciences Inc., Cayman Chemical Company, Biosynth Carbosynth AG, Curtana Pharmaceuticals Inc., VBI Vaccines Inc.

North America was the largest region in the medulloblastoma drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medulloblastoma drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the medulloblastoma drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medulloblastoma drug market consists of sales of chemotherapy drugs, targeted therapies, supportive care medications, steroids, and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medulloblastoma Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on medulloblastoma drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for medulloblastoma drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medulloblastoma drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Dianhydrogalactitol; Investigational Medicinal Product 5471; Ipilimumab; Indoximod; Other Types
• 2) By Product: Chemotherapy Drugs; Targeted Therapy Drugs; Radiation Therapy Drugs
• 3) By Route Of Administration: Intravenous; Oral; Intrathecal
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-Users: Hospitals; Homecare; Speciality Centres; Other End-Users
• Subsegments:
• 1) By Dianhydrogalactitol: Dianhydrogalactitol Oral Formulations; Dianhydrogalactitol Intravenous Formulations
• 2) By Investigational Medicinal Product 5471: Oral Investigational Medicinal Product 5471; Intravenous Investigational Medicinal Product 5471
• 3) By Ipilimumab: Ipilimumab Monotherapy; Ipilimumab Combination Therapy
• 4) By Indoximod: Indoximod Oral Formulations; Indoximod Combination Therapy
• 5) By Other Types: Temozolomide; Lomustine; Cyclophosphamide; Targeted Therapy Drugs
• Companies Mentioned:Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Medulloblastoma Drug Market Characteristics

3. Medulloblastoma Drug Market Trends And Strategies

4. Medulloblastoma Drug Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Medulloblastoma Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Medulloblastoma Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Medulloblastoma Drug Market Growth Rate Analysis
• 5.4. Global Medulloblastoma Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Medulloblastoma Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Medulloblastoma Drug Total Addressable Market (TAM)

6. Medulloblastoma Drug Market Segmentation

• 6.1. Global Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dianhydrogalactitol
• Investigational Medicinal Product 5471
• Ipilimumab
• Indoximod
• Other Types
• 6.2. Global Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Drugs
• Targeted Therapy Drugs
• Radiation Therapy Drugs
• 6.3. Global Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Oral
• Intrathecal
• 6.4. Global Medulloblastoma Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Medulloblastoma Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End-Users
• 6.6. Global Medulloblastoma Drug Market, Sub-Segmentation Of Dianhydrogalactitol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dianhydrogalactitol Oral Formulations
• Dianhydrogalactitol Intravenous Formulations
• 6.7. Global Medulloblastoma Drug Market, Sub-Segmentation Of Investigational Medicinal Product 5471, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Investigational Medicinal Product 5471
• Intravenous Investigational Medicinal Product 5471
• 6.8. Global Medulloblastoma Drug Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ipilimumab Monotherapy
• Ipilimumab Combination Therapy
• 6.9. Global Medulloblastoma Drug Market, Sub-Segmentation Of Indoximod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indoximod Oral Formulations
• Indoximod Combination Therapy
• 6.10. Global Medulloblastoma Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Temozolomide
• Lomustine
• Cyclophosphamide
• Targeted Therapy Drugs

7. Medulloblastoma Drug Market Regional And Country Analysis

• 7.1. Global Medulloblastoma Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Medulloblastoma Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Medulloblastoma Drug Market

• 8.1. Asia-Pacific Medulloblastoma Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Medulloblastoma Drug Market

• 9.1. China Medulloblastoma Drug Market Overview
• 9.2. China Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Medulloblastoma Drug Market

• 10.1. India Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Medulloblastoma Drug Market

• 11.1. Japan Medulloblastoma Drug Market Overview
• 11.2. Japan Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Medulloblastoma Drug Market

• 12.1. Australia Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Medulloblastoma Drug Market

• 13.1. Indonesia Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Medulloblastoma Drug Market

• 14.1. South Korea Medulloblastoma Drug Market Overview
• 14.2. South Korea Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Medulloblastoma Drug Market

• 15.1. Western Europe Medulloblastoma Drug Market Overview
• 15.2. Western Europe Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Medulloblastoma Drug Market

• 16.1. UK Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Medulloblastoma Drug Market

• 17.1. Germany Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Medulloblastoma Drug Market

• 18.1. France Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Medulloblastoma Drug Market

• 19.1. Italy Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Medulloblastoma Drug Market

• 20.1. Spain Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Medulloblastoma Drug Market

• 21.1. Eastern Europe Medulloblastoma Drug Market Overview
• 21.2. Eastern Europe Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Medulloblastoma Drug Market

• 22.1. Russia Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Medulloblastoma Drug Market

• 23.1. North America Medulloblastoma Drug Market Overview
• 23.2. North America Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Medulloblastoma Drug Market

• 24.1. USA Medulloblastoma Drug Market Overview
• 24.2. USA Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Medulloblastoma Drug Market

• 25.1. Canada Medulloblastoma Drug Market Overview
• 25.2. Canada Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Medulloblastoma Drug Market

• 26.1. South America Medulloblastoma Drug Market Overview
• 26.2. South America Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Medulloblastoma Drug Market

• 27.1. Brazil Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Medulloblastoma Drug Market

• 28.1. Middle East Medulloblastoma Drug Market Overview
• 28.2. Middle East Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Medulloblastoma Drug Market

• 29.1. Africa Medulloblastoma Drug Market Overview
• 29.2. Africa Medulloblastoma Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Medulloblastoma Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Medulloblastoma Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Medulloblastoma Drug Market Competitive Landscape And Company Profiles

• 30.1. Medulloblastoma Drug Market Competitive Landscape
• 30.2. Medulloblastoma Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Medulloblastoma Drug Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GSK plc
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Biocon Limited
• 31.6. Teva Pharmaceutical Industries Ltd
• 31.7. Eisai Co. Ltd.
• 31.8. Ipsen S.A.
• 31.9. Daiichi Sankyo Co. Ltd.
• 31.10. Lumos Pharma Inc.
• 31.11. Biodexa Pharmaceuticals plc
• 31.12. Eagle Biosciences Inc.
• 31.13. Cayman Chemical Company
• 31.14. Biosynth Carbosynth AG
• 31.15. Curtana Pharmaceuticals Inc.

32. Global Medulloblastoma Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Medulloblastoma Drug Market

34. Recent Developments In The Medulloblastoma Drug Market

35. Medulloblastoma Drug Market High Potential Countries, Segments and Strategies

• 35.1 Medulloblastoma Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Medulloblastoma Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Medulloblastoma Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer